[1] Sy-Go JPT, Herrmann SM, Seshan SV. Monoclonal gammopathy-related kidney diseases[J].Adv Chronic Kidney Dis,2022,29(2):86-102.e1.DOI:10.1053/j.ackd.2022.01.004.
[2] Rendo M, Franks TJ, Galvin JR, et al. Autologous stem cell transplantation in the treatment of pulmonary light chain deposition disease[J].Chest,2021,160(1):e13-e17.DOI:10.1016/j.chest.2021.02.041.
[3] Lin ZS, Zhang X, Li DY, et al. Clinicopathological features and outcomes of coexistent light chain cast nephropathy and light chain deposition disease in patients with newly diagnosed multiple myeloma[J].J Clin Pathol,2021,29:207449.DOI:10.1136/jclinpath-2021-207449.
[4] Milani P, Basset M, Curci P, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function[J].Blood Adv,2020,4(7):1321-1324.DOI:10.1182/bloodadvances.2020001553.
[5] 沈扬,张丽红. 轻链沉积病的临床诊治进展[J]. 现代肿瘤医学,2023,31(21):4050-4054.DOI:10.3969/j.issn.1672-4992.2023.21.028.
[6] 杨乐斌,张益民,柯晓斌,等. 血清免疫固定电泳阴性的肾轻链沉积病1例[J]. 中国中西医结合肾病杂志,2022,23(8):739-740.DOI:10.3969/j.issn.1009-587X.2022.08.028.
[7] 田秀娟,何娟,柳红昌. 轻链沉积病合并肾脏损害的临床特点及预后分析[J]. 重庆医学,2021,50(14):2423-2428.DOI:10.3969/j.issn.1671-8348.2021.14.018.
[8] 宁少雄,岳书玲,唐梦霞,等. 轻链沉积病合并轻链管型肾病所致肾衰竭一例报道[J]. 临床肾脏病杂志,2020,20(6):519-521.DOI:10.3969/j.issn.1671-2390.2020.06.016.
[9] 李沂蔓,刘春梅,杨亦彬. 轻链沉积性肾病误诊为高血压肾病一例并文献复习[J]. 海南医学,2020,31(2):256-258.DOI:10.3969/j.issn.1003-6350.2020.02.034.
[10] 张园,范芸,梁丹丹,等. 轻链、重链沉积病患者血液和尿液补体活化产物的研究[J]. 肾脏病与透析肾移植杂志,2021,30(1):37-42.DOI:10.3969/j.issn.1006-298X.2021.01.007.
[11] 傅兰君,陈红波,项晓骏,等. 单克隆免疫球蛋白相关性肾损伤的临床表现分析和免疫球蛋白分型[J]. 浙江医学,2020,42(11):1193-1195.DOI:10.12056/j.issn.1006-2785.2020. 42.11.2019-3149.
[12] Bergner R, Hoffmann M, Uppenkamp M, et al. The urine light chain/glomerular filtration rate (GFR) quotient shows a high sensitivity and specificity to detect cast nephropathy in monoclonal light chain disease[J].Eur J Haematol,2021,106(6):836-841.DOI:10.1111/ejh.13616.
[13] Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma[J].Kidney Int,2021,99(3):570-580.DOI:10.1016/j.kint.2020.11.010.
[14] Bu L, Javaugue V, Chauvet S, et al. Light chain-only immunotactoid glomerulopathy: a case report[J].Am J Kidney Dis,2023,81(5):611-615.DOI:10.1053/j.ajkd.2022.08.025.
[15] Del Pozo-Yauner L, Herrera GA, Perez Carreon JI, et al. Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe[J].Front Immunol,2023,14:1203425.DOI:10.3389/fimmu.2023.1203425.
[16] Javaugue V, Rocha AB, Said SM, et al. Clinicopathologic and proteomic characteristics of intratubular cytoplasmic AL amyloidosis[J].Kidney Int,2022,102(4):926-929.DOI:10.1016/j.kint.2022.07.020.
[17] Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy[J].Blood Cancer J,2023,13(1):46.DOI:10.1038/s41408-023-00806-w.
[18] Lin ZS, Qin AB, Wang SX, et al. A non-invasive differential diagnostic model for light chain cast nephropathy in newly diagnosed multiple myeloma patients with renal involvement: a multicenter study[J].J Nephrol,2021,34(4):1169-1177.DOI:10.1007/s40620-020-00926-7.
[19] Lin ZS, Zhang X, Yu XJ, et al. Crystalline appearance in light chain cast nephropathy is associated with higher early mortality in patients with newly diagnosed multiple myeloma[J].Int Immunopharmacol,2021,98:107875.DOI:10.1016/j.intimp.2021.107875.
[20] Lin ZS, Zhou FD. Crystals in myeloma cast nephropathy[J].QJM,2021,114(10):753-754.DOI:10.1093/qjmed/hcab197.
[21] Menè P, Moioli A, Stoppacciaro A, et al. Acute kidney injury in monoclonal gammopathies[J].J Clin Med,2021,10(17):3871.DOI:10.3390/jcm10173871.
[22] Mizuno S, Kosukegawa H. Amyloid cast nephropathy with systemic AL amyloidosis[J].Int J Hematol,2021,113(1):1-2.DOI:10.1007/s12185-020-03036-z.
[23] Ponsford AH, Ryan TA, Raimondi A, et al. Live imaging of intra-lysosome pH in cell lines and primary neuronal culture using a novel genetically encoded biosensor[J].Autophagy,2021,17(6):1500-1518.DOI:10.1080/15548627.2020.1771858.
[24] Rafat C, Zaworski J, Luque Y, et al. Noninvasive screening of vancomycin-associated cast nephropathy[J].Kidney Int,2022,101(2):425.DOI:10.1016/j.kint.2021.06.039.
[25] Ratnayake C, Gibbs SDJ, Lee D. Kidney outcomes and prognostic factors of myeloma associated acute kidney injury in the contemporary era[J].Nephrology (Carlton),2023,28(10):561-566.DOI:10.1111/nep.14195.
[26] Reiter T, Pajenda S, O'Connell D, et al. Renal expression of light chain binding proteins[J].Front Med (Lausanne),2021,7:609582.DOI:10.3389/fmed.2020.609582.
[27] Ribas A, Puche A, Gimeno J, et al. Podocytopathy in patients with monoclonal gammopathy: three patients and literature review[J].Clin Kidney J,2021,15(3):417-424.DOI:10.1093/ckj/sfab176.
[28] Royal V, Leung N, Troyanov S, et al. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study[J].Blood,2020,135(21):1833-1846.DOI:10.1182/blood. 2019003807.
[29] Szabo AG, Thorsen J, Iversen KF, et al. Clinically-suspected cast nephropathy: a retrospective, national, real-world study[J].Am J Hematol,2020,95(11):1352-1360.DOI:10.1002/ajh.25959.
[30] Try M, Harel S. Renal failure in multiple myeloma: specific management issues[J].Bull Cancer,2023,7:S0007-4551(23)00042-5.DOI:10.1016/j.bulcan.2022. 12.015.
[31] Yadav P, Sathick IJ, Leung N, et al. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study[J].Blood Cancer J,2020,10(3):28.DOI:10.1038/s41408-020-0295-4.
[32] Yong ZH, Yu XJ, Lin ZS, et al. Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report[J].BMC Nephrol,2021,22(1):6.DOI:10.1186/s12882-020-02204-x.
|